Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is C1q nephropathy associated with a WDR19 gene mutation? A case report.

Hippokratia·2022

Same author

Deactivation of cardiovascular implantable electronic devices in patients nearing end of life : Reality or only recommendation?

Herz·2019

Same author

Individual programming of current multiprogrammable pacemakers : Still unsatisfactory?

Herz·2018

Same author

Hysterosalpingography prior to the gonadotropin stimulated intrauterine insemination improves clinical pregnancy rates in women with unexplained infertility.

Clinical and experimental obstetrics & gynecology·2018

Same author

[26-year-old man with dyspnea and palpitation].

Deutsche medizinische Wochenschrift (1946)·2013

Same author

[A case of cardiac AA amyloidosis].

Deutsche medizinische Wochenschrift (1946)·2012

Same journal

Deutsche medizinische Wochenschrift (1946)·2026

Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026

Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026

Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026

Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026

Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

[Amiodarone-induced liver dysfunctions].

N Gassanov¹, E Caglayan, E Erdmann

¹Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln. Natig.Gassanov@uk-koeln.de

Deutsche Medizinische Wochenschrift (1946)

|July 1, 2010

Summary

This summary is machine-generated.

Amiodarone, an antiarrhythmic drug, can cause severe liver damage due to its accumulation in the liver. This review discusses amiodarone-induced liver injury and its management challenges.

Related Experiment Videos

Last Updated: Jun 11, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Area of Science:

Pharmacology
Hepatology
Cardiology

Background:

Amiodarone is a potent antiarrhythmic agent used for tachyarrhythmias.
Its lipophilic nature leads to significant accumulation in hepatic tissues, potentially exceeding serum levels by 500-fold.

Observation:

The drug's long half-life and lipophilicity contribute to sustained liver exposure.
Hepatotoxicity can manifest long after amiodarone discontinuation.

Findings:

Amiodarone-induced liver dysfunction presents diagnostic and therapeutic challenges.
Potential severe outcomes include acute liver failure, cirrhosis, and the need for liver transplantation.

Implications:

Understanding amiodarone's hepatotoxic potential is crucial for patient safety.
Clinical vigilance and proactive management strategies are essential for patients on amiodarone therapy.